BeiGene (STU:49B) Stock Based Compensation : €352 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Stock Based Compensation?

BeiGene's Stock Based Compensation for the three months ended in Mar. 2024 was €82 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was €352 Mil.

BeiGene Stock Based Compensation Historical Data

The historical data trend for BeiGene's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Stock Based Compensation Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

120.74

150.82

213.03

286.18

337.11

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Stock Based Compensation	Get a 7-Day Free Trial															70.35	95.41	89.95	85.21	81.58

BeiGene Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €352 Mil.

BeiGene Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of BeiGene's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (STU:49B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (STU:49B) Headlines

No Headlines